Takehiko Okamura is a Chief Director of Department of Urology at J.A. Aichi Anjo Kosei Hospital. After bladder carcinogenesis research at First Department of Pathology, Nagoya City University Medical School, Nagoya, Japan, Okamura completed his Ph.D. degree in medical genetics in 1988. During the time, he worked with both pathologists and urologists; one of the works was enzyme phenotypes of human bladder tumors and animal model. From 1989 to 1991, he worked as Research Fellow at Department of Pathology and Microbiology, University of Nebraska Medical Center, where the boss was one of the famous bladder carcinogenesis researchers, Dr. Samuel M. Cohen. He aggressively researched bladder carcinogenesis and also molecular biology. After coming back to Japan, he worked with his colleague on lectin immunohistochemical evaluation of human bladder carcinomas or sequencing analysis of ras genes in rat urinary bladder tumors. Corroborating with First Department of Pathology, Nagoya City University Medical School, he had reached molecular biological findings of human urinary bladder. He transferred to Meijo Hospital, Nagoya, Japan in 1997 and J.A. Aichi Anjo Kosei Hospital in 2005. He has been continuing clinical and translational research on BCG more than 20 years. Major works are Immunohistochemical evaluation of p53, PCNA and bcl-2 expression during BCG intravesical instillation therapy for superficial bladder cancers, prevention of the recurrence of superficial bladder cancers: intravesical instillation of BCG versus BCG plus epirubicin, and efficacy of bacillus calmette-guerin in the treatment of superficial ladder cancer: the impact of previous intravesical treatment.
Biography Updated on 3 January 2011